Personalized support begins with MyAlcon Together
The MyAlcon Together Patient Support program has been designed to help meet each patient’s unique needs and help them get the most out of treatment with RHOPRESSA®
Customizable program offerings include:
Personalized nurse support that can help educate patients about their RHOPRESSA® prescription
Nurses provide personalized telephone support and education in over 200 languages to answer general questions about glaucoma and their IOP-lowering treatment
Patients can save on prescriptions with the Alcon Savings Card
Eligible, commercially insured patients may pay as little as $30 with the Savings Card*
Tips, reminders, and resources that may help keep their RHOPRESSA® treatment on track
Patients can receive text and email messages with tips for instilling drops, prescription refills, and other useful resources to help them stay on top of their prescription
Encourage your patients to enroll in the MyAlcon Together Patient Support program
Alcon is committed to supporting patient access to medications
IOP=Intraocular pressure.
IMPORTANT SAFETY INFORMATION
Warnings and Precautions
Bacterial Keratitis: There have been reports of bacterial keratitis associated with the use of multiple-dose containers of topical ophthalmic products. These containers had been inadvertently contaminated by patients who, in most cases, had a concurrent corneal disease or a disruption of the ocular epithelial surface.
INDICATIONS AND USAGE
Rhopressa® (netarsudil ophthalmic solution) 0.02% is indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
Contact Lenses: Contact lenses should be removed prior to instillation of Rhopressa® and may be inserted 15 minutes following its administration.
Adverse Reactions
The most common ocular adverse reaction observed in controlled clinical studies with Rhopressa® dosed once daily was conjunctival hyperemia, reported in 53% of patients. Six percent of patients discontinued therapy due to conjunctival hyperemia. Other common (approximately 20%) adverse reactions were: corneal verticillata, instillation site pain, and conjunctival hemorrhage. Instillation site erythema, corneal staining, blurred vision, increased lacrimation, erythema of eyelid, and reduced visual acuity were reported in 5-10% of patients.
The corneal verticillata seen in Rhopressa®- treated patients were first noted at 4 weeks of daily dosing. This reaction did not result in any apparent visual functional changes. Most corneal verticillata resolved upon discontinuation of treatment.
Please click here for full prescribing information for Rhopressa®.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
DOSAGE AND ADMINISTRATION
The recommended dosage is one drop in the affected eye(s) once daily in the evening.